Condition
Gastrointestinal Dysmotility
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (2)
Trial Status
Completed4
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04880538CompletedPrimary
Enteric Neural Precursor Cells (ENPC) in the Human Gut
NCT04872452Not ApplicableWithdrawn
Analysis of Cutaneous Nerve Biopsies in Gastrointestinal Motility Disorders
NCT01280344Phase 2CompletedPrimary
Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function
NCT01296620Phase 3CompletedPrimary
Ulimorelin Study of Efficacy and Safety (ULISES 008)
NCT01285570Phase 3CompletedPrimary
Ulimorelin Study of Efficacy and Safety (ULISES 007)
Showing all 5 trials